166 related articles for article (PubMed ID: 11302475)
21. Releasing the Brakes on the Fibrinolytic System in Pulmonary Emboli: Unique Effects of Plasminogen Activation and α2-Antiplasmin Inactivation.
Singh S; Houng A; Reed GL
Circulation; 2017 Mar; 135(11):1011-1020. PubMed ID: 28028005
[TBL] [Abstract][Full Text] [Related]
22. Activation of fibrinolysis in the pericardial cavity after cardiopulmonary bypass.
Khalil PN; Ismail M; Kalmar P; von Knobelsdorff G; Marx G
Thromb Haemost; 2004 Sep; 92(3):568-74. PubMed ID: 15351853
[TBL] [Abstract][Full Text] [Related]
23. Relationship of fibrinolysis and platelet function to bleeding after cardiopulmonary bypass.
Ray MJ; Marsh NA; Hawson GA
Blood Coagul Fibrinolysis; 1994 Oct; 5(5):679-85. PubMed ID: 7865673
[TBL] [Abstract][Full Text] [Related]
24. Effect of a synthetic carboxy-terminal peptide of alpha(2)-antiplasmin on urokinase-induced fibrinolysis.
Lee KN; Jackson KW; McKee PA
Thromb Res; 2002 Feb; 105(3):263-70. PubMed ID: 11927133
[TBL] [Abstract][Full Text] [Related]
25. Aprotinin reduces cardiopulmonary bypass-induced blood loss and inhibits fibrinolysis without influencing platelets.
Orchard MA; Goodchild CS; Prentice CR; Davies JA; Benoit SE; Creighton-Kemsford LJ; Gaffney PJ; Michelson AD
Br J Haematol; 1993 Nov; 85(3):533-41. PubMed ID: 7510990
[TBL] [Abstract][Full Text] [Related]
26. Effect of low-dose aprotinin on coagulation and fibrinolysis in cardiopulmonary bypass.
Kawasuji M; Ueyama K; Sakakibara N; Tedoriya T; Matsunaga Y; Misaki T; Watanabe Y
Ann Thorac Surg; 1993 May; 55(5):1205-9. PubMed ID: 7684219
[TBL] [Abstract][Full Text] [Related]
27. Post-thrombolysis haemostasis changes after rt-PA treatment in acute cerebral infarct. Correlations with cardioembolic aetiology and outcome.
Sun X; Berthiller J; Derex L; Trouillas P; Diallo L; Hanss M
J Neurol Sci; 2015 Feb; 349(1-2):77-83. PubMed ID: 25619569
[TBL] [Abstract][Full Text] [Related]
28. Influence of soluble fibrin on reaction kinetics of plasmin type 1 and type 2 with alpha2-antiplasmin.
Ries M; Zenker M
Blood Coagul Fibrinolysis; 2003 Feb; 14(2):203-9. PubMed ID: 12632033
[TBL] [Abstract][Full Text] [Related]
29. A randomized trial of the topical effect of antifibrinolytic epsilon aminocaproic Acid on coronary artery bypass surgery without cardiopulmonary bypass.
Gurian DB; Meneghini A; Abreu LC; Murad N; Matos LL; Pires AC; Valenti VE; Breda JR
Clin Appl Thromb Hemost; 2014 Sep; 20(6):615-20. PubMed ID: 23434921
[TBL] [Abstract][Full Text] [Related]
30. Impaired activation of the fibrinolytic system in children with Henoch-Schönlein purpura: beneficial effect of hydrocortisone plus Sigma-aminocaproic acid therapy on disappearance rate of cutaneous vasculitis and fibrinolysis.
Prandota J; Pankow-Prandota L; Kotecki L
Am J Ther; 2001; 8(1):11-9. PubMed ID: 11304653
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of aprotinin, epsilon aminocaproic acid, or combination in cyanotic heart disease.
Chauhan S; Kumar BA; Rao BH; Rao MS; Dubey B; Saxena N; Venugopal P
Ann Thorac Surg; 2000 Oct; 70(4):1308-12. PubMed ID: 11081890
[TBL] [Abstract][Full Text] [Related]
32. Complete inhibition of fibrinolysis by sustained carboxypeptidase B activity: the role and requirement of plasmin inhibitors.
Walker JB; Bajzar L
J Thromb Haemost; 2007 Jun; 5(6):1257-64. PubMed ID: 17389009
[TBL] [Abstract][Full Text] [Related]
33. Effects of nafamostat mesilate and minimal-dose aprotinin on blood-foreign surface interactions in cardiopulmonary bypass.
Kaminishi Y; Hiramatsu Y; Watanabe Y; Yoshimura Y; Sakakibara Y
Ann Thorac Surg; 2004 Feb; 77(2):644-50. PubMed ID: 14759453
[TBL] [Abstract][Full Text] [Related]
34. Effects of epsilon-aminocaproic acid and aprotinin on leukocyte-platelet adhesion in patients undergoing cardiac surgery.
Greilich PE; Brouse CF; Rinder CS; Smith BR; Sandoval BA; Rinder HM; Eberhart RC; Jessen ME
Anesthesiology; 2004 Feb; 100(2):225-33. PubMed ID: 14739793
[TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetics of ε-Aminocaproic Acid in Neonates Undergoing Cardiac Surgery with Cardiopulmonary Bypass.
Eaton MP; Alfieris GM; Sweeney DM; Angona RE; Cholette JM; Venuto C; Anderson B
Anesthesiology; 2015 May; 122(5):1002-9. PubMed ID: 25723765
[TBL] [Abstract][Full Text] [Related]
36. Intraoperative antifibrinolysis and blood-saving techniques in cardiac surgery. Prospective trial of 3 antifibrinolytic drugs.
Penta de Peppo A; Pierri MD; Scafuri A; De Paulis R; Colantuono G; Caprara E; Tomai F; Chiariello L
Tex Heart Inst J; 1995; 22(3):231-6. PubMed ID: 7580360
[TBL] [Abstract][Full Text] [Related]
37. Like fibrin, (DD)E, the major degradation product of crosslinked fibrin, protects plasmin from inhibition by alpha2-antiplasmin.
Lee AY; Fredenburgh JC; Stewart RJ; Rischke JA; Weitz JI
Thromb Haemost; 2001 Mar; 85(3):502-8. PubMed ID: 11307822
[TBL] [Abstract][Full Text] [Related]
38. epsilon-Aminocaproic acid plasma levels during cardiopulmonary bypass.
Bennett-Guerrero E; Sorohan JG; Canada AT; Ayuso L; Newman MF; Reves JG; Mythen MG
Anesth Analg; 1997 Aug; 85(2):248-51. PubMed ID: 9249095
[TBL] [Abstract][Full Text] [Related]
39. Low-dose and high-dose aprotinin improve hemostasis in coronary operations.
Speekenbrink RG; Wildevuur CR; Sturk A; Eijsman L
J Thorac Cardiovasc Surg; 1996 Aug; 112(2):523-30. PubMed ID: 8751522
[TBL] [Abstract][Full Text] [Related]
40. Perioperative renal outcome in cardiac surgical patients with preoperative renal dysfunction: aprotinin versus epsilon aminocaproic acid.
Maslow AD; Chaudrey A; Bert A; Schwartz C; Singh A
J Cardiothorac Vasc Anesth; 2008 Feb; 22(1):6-15. PubMed ID: 18249324
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
